According to Florida statute, ''A practitioner, in good faith and in the course of his or her professional practice only, may prescribe, administer, dispense, mix, or otherwise prepare a controlled substance.'' Fla. Stat. 893.05(1)(a) (2022). Further, a ''practitioner'' as defined by Florida statute includes ''a physician assistant licensed under chapter 458 or 459.'' [3] *Id.* at 893.02(23).

Here, the undisputed evidence in the record is that Respondent is not currently a licensed practitioner in Florida, and a physician assistant must be a licensed practitioner to dispense a controlled substance in Florida. Thus, because Respondent lacks authority to handle controlled substances in Florida, Respondent is not eligible to maintain a DEA registration based in Florida. Accordingly, the Agency will order that Respondent's DEA registration be revoked.

Order

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No. MD4826915 issued to Adley Dasilva, P.A. Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(f), I hereby deny any pending applications of Adley Dasilva, P.A., to renew or modify this registration, as well as any other pending application of Adley Dasilva, P.A., for additional registration in Florida. This Order is effective December 19, 2022.

Signing Authority

This document of the Drug Enforcement Administration was signed on November 9, 2022, by Administrator Anne Milgram. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the **Federal Register**.

Heather Achbach,

Federal Register Liaison Officer, Drug Enforcement Administration.

[FR Doc. 2022–25103 Filed 11–17–22; 8:45 am]

BILLING CODE 4410–09–P

[3] Chapter 458 regulates medical practice and applies to Respondent. GX B, at 2.

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1096]

Bulk Manufacturer of Controlled Substances Application: Vici Health Sciences, LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Vici Health Sciences, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before January 17, 2023. Such persons may also file a written request for a hearing on the application on or before January 17, 2023.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov*. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on August 5, 2022, Vici Health Sciences, LLC, 6655 Amberton Drive, Suite N, Elkridge, Maryland 21075, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Ibogaine	7260	I
Fentanyl related-compounds as defined in 21 CFR 1308.11(h).	9850	I

The company plans to bulk manufacture the listed controlled substances or their intermediates for sale to its customers. No other activities for these drug codes are authorized for this registration.

Kristi O'Malley,

Assistant Administrator.

[FR Doc. 2022–25174 Filed 11–17–22; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the Clean Water Act

On November 14, 2022, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the Southern District of Illinois in the lawsuit entitled *United States and the State of Illinois* v. *Prairie State Solar, LLC,* Civil Action No. 3:22–cv–02660.

In this case, the United States and the State seek to resolve claims against Defendant Prairie State Solar, LLC under the Clean Water Act. The United States and the State allege Prairie States violated its state stormwater permit during the construction of a large-scale solar farm in Perry County, Illinois. The proposed Consent Decree requires Prairie State to perform injunctive relief measures to ensure compliance until construction is complete and the stormwater permit is terminated. The Consent Decree also requires Prairie State to pay a civil penalty of $225,000, with $157,500 to the United States and $67,500 to the State of Illinois.

The publication of this notice opens a period for public comment on the Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States and The State of Illinois* v. *Prairie State Solar,* D.J. Ref. No. 90–5–1–1–12558/1. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	*Send them to:*
By email	*pubcomment-ees.enrd@usdoj.gov.*
By mail	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department website: *https://www.justice.gov/enrd/consent-decrees.*